Last reviewed 2026-05-14 · How we verify

JNJ-74699157

Janssen Research & Development, LLC · Phase 1 active Small molecule

JNJ-74699157 is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 1 development. Also known as: ARS-3248.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Janssen Research & Development, LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	JNJ-74699157
Also known as	ARS-3248
Sponsor	Janssen Research & Development, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JNJ-74699157 CI brief — competitive landscape report
JNJ-74699157 updates RSS · CI watch RSS
Janssen Research & Development, LLC portfolio CI

Frequently asked questions about JNJ-74699157

What is JNJ-74699157?

JNJ-74699157 is a Small molecule drug developed by Janssen Research & Development, LLC.

Who makes JNJ-74699157?

JNJ-74699157 is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).

Is JNJ-74699157 also known as anything else?

JNJ-74699157 is also known as ARS-3248.

What development phase is JNJ-74699157 in?

JNJ-74699157 is in Phase 1.

Manufacturer: Janssen Research & Development, LLC — full pipeline
Also known as: ARS-3248

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing